Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits

NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · Awarded

Buyer
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
Status
Awarded
Country
United Kingdom
Region
England
Sector
Manufacturing
Reference
FaT-ocds-h6vhtk-02bcb3
Published
2021-06-16

Tender summary

All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. Due to considerable increase in the demand for the test the AWMGL intends to award a two year contract (for a period of 12 months with the option to extend for…

This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.

Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.

Register for full access

IT tenders · Construction tenders · Sitemap